Objective To study the therapeutic efficacy of telbivudine in patients with decompensated cirrhosis resulting from chronic hepatitis B.Methods A total of 64 patients were divided into two groups, group one patients (n = 34) were received telbivudine 600mg and group two patients (n = 30) were treated with Lamivudine 100mg, orally per day for 48 weeks.The changes were observed at different times including virological and biochemical markers, PT and Child-Pugh score after antiviral therapy.Results In the telbivudine group, the mean serum HBV DNA level was (5.35 ± 0.58) log10 copies/ml, and the mean serum HBV DNA levels were (1.88 ± 0.84) , (2.11 ± 0.84) , (2.17 ± 0.74) and (2.36 ± 0.57) log10 copies/ml at 12, 24, 36 and 48 weeks, respectively.The mean reductions in serum HBV DNA levels were significantly greater in telbivudine group than lamivudine group (P < 0.05) .After 24 weeks of therapy ALT, AST, albumin, total bilirubin and Child-Pugh scores were improved in the telbivdine group (P < 0.05) .Conclusion Telbivudine rapidly and effectively inhibits the replication of HBV in cirrhosis resulting from chronic hepatitis B after 48-weeks of treatment and the reduction in the level of HBV DNA also improves the liver function, PT and Child-Pugh score.
DownLoad: